Further, A*Star has chosen Agilent to offer automation technologies to biomedical researchers, enabling efficient drug screening in one location.
A*STAR has now deployed Agilent’s dual BioCel 1200 integrated system, which automates and coordinates the various processes of high-throughput screening, including compound management, assay plate preparation and experiment replication, to ensure high-quality data while saving time and reducing the possibility of human error.
The platform is expected to enhance ongoing drug discovery projects at the Singapore Screening Center for discovering anti-bacterial drugs using a novel whole animal-screening platform.
ETC CEO Alex Matter said the location of Agilent’s technology platform within ETC’s newly set up Singapore Screening Centre will not only enhance their ability to produce proprietary drugs for Singapore, but also provide a platform with which to engage a diversity of biomedical research players from across the world.